Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Albano L et al. | OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. | 2013 | Transplantation | pmid:23982340 |
Marcos A et al. | Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. | 2004 | Transplantation | pmid:15480160 |
Jain A et al. | Pregnancy after liver transplantation under tacrolimus. | 1997 | Transplantation | pmid:9293865 |
Garrity ER and Mehra MR | An update on clinical outcomes in heart and lung transplantation. | 2004 | Transplantation | pmid:15201689 |
First MR and Fitzsimmons WE | New drugs to improve transplant outcomes. | 2004 | Transplantation | pmid:15201693 |
Takaya S et al. | The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. | 1992 | Transplantation | pmid:1371195 |
Boldt A et al. | The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo. | 2006 | Transplantation | pmid:16906043 |
Sheikh AM et al. | Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. | 1999 | Transplantation | pmid:10440408 |
Gaber AO et al. | Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. | 2013 | Transplantation | pmid:23423269 |
Fujita T et al. | Prolonged survival of rat skin allograft by treatment with FK506 ointment. | 1997 | Transplantation | pmid:9326422 |
Pratschke J et al. | Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. | 1997 | Transplantation | pmid:9326428 |
Jain AB et al. | Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. | 2004 | Transplantation | pmid:15077034 |
High KP | The antimicrobial activities of cyclosporine, FK506, and rapamycin. | 1994 | Transplantation | pmid:7517076 |
Jain A et al. | Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection. | 2014 | Transplantation | pmid:25285953 |
Bierer BE et al. | Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. | 1990 | Transplantation | pmid:1694317 |
Eiras G et al. | Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. | 1990 | Transplantation | pmid:1694318 |
Tze WJ et al. | In vitro effects of FK-506 on human and rat islets. | 1990 | Transplantation | pmid:1694319 |
Maes BD et al. | Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. | 2001 | Transplantation | pmid:11726827 |
Moxey-Mims MM et al. | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1998 | Transplantation | pmid:9521193 |
Hytiroglou P et al. | FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. | 1993 | Transplantation | pmid:7506452 |
Jordan ML et al. | Long-term results of pancreas transplantation under tacrolius immunosuppression. | 1999 | Transplantation | pmid:10075592 |
Min DI et al. | Circadian variation of tacrolimus disposition in liver allograft recipients. | 1996 | Transplantation | pmid:8900327 |
Ciancio G et al. | Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. | 2011 | Transplantation | pmid:21107305 |
Jindal RM et al. | Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7519799 |
Reddy KS et al. | Simultaneous kidney-pancreas transplantation without antilymphocyte induction. | 2000 | Transplantation | pmid:10653379 |
Borrows R et al. | Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. | 2006 | Transplantation | pmid:16421488 |
Arzouk N et al. | Interaction between tacrolimus and fumagillin in two kidney transplant recipients. | 2006 | Transplantation | pmid:16421493 |
Naesens M et al. | Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. | 2008 | Transplantation | pmid:18431234 |
Dean PG et al. | Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. | 2008 | Transplantation | pmid:18431244 |
Laskow DA et al. | An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. | 1996 | Transplantation | pmid:8878381 |
Shoji T et al. | Operational tolerance to class I disparate lungs can be induced despite pretransplant immunization with class I allopeptides. | 2007 | Transplantation | pmid:18091523 |
McLaren A | Tacrolimus pharmacogenetics: bringing the laboratory into the clinic. | 2003 | Transplantation | pmid:14705621 |
Roberts CA et al. | Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. | 2002 | Transplantation | pmid:12364862 |
Klein IH et al. | Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. | 2002 | Transplantation | pmid:11907418 |
Vincenti F et al. | A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. | 2002 | Transplantation | pmid:11907427 |
Ringe B et al. | A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. | 2001 | Transplantation | pmid:11258429 |
Cantarovich D et al. | Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. | 2005 | Transplantation | pmid:15714172 |
Nguyen L et al. | Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat cutaneous warts in a series of four pediatric renal allograft recipients. | 2012 | Transplantation | pmid:22960763 |
Steinmüller TM et al. | The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. | 1994 | Transplantation | pmid:7524203 |
Singh N et al. | Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. | 1994 | Transplantation | pmid:7524204 |
Langrehr JM et al. | Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. | 1992 | Transplantation | pmid:1384185 |
Egashira K et al. | Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. | 2003 | Transplantation | pmid:12698101 |
Hu H et al. | Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. | 2003 | Transplantation | pmid:12698107 |
Fredericks S and Holt DW | TGF-beta quantitation can be tricky. | 1999 | Transplantation | pmid:10480399 |
Peng Y et al. | Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. | 2013 | Transplantation | pmid:23263506 |
Kuypers DR et al. | Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. | 2013 | Transplantation | pmid:23263559 |
White M et al. | Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. | 2006 | Transplantation | pmid:17006323 |
Herold KC et al. | Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. | 1993 | Transplantation | pmid:7678356 |
Holman MJ et al. | FK506-associated thrombotic thrombocytopenic purpura. | 1993 | Transplantation | pmid:7678357 |
Todo S et al. | Small intestinal transplantation in humans with or without the colon. | 1994 | Transplantation | pmid:7512291 |